...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Dengue structural proteins as antiviral drug targets: Current status in the drug discovery & development
【24h】

Dengue structural proteins as antiviral drug targets: Current status in the drug discovery & development

机译:登革热结构蛋白作为抗病毒药物靶点:药物发现与发育的当前状态

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Dengue virus belongs to the class of RNA viruses and subclass of enveloped single-stranded positive-sense RNA virus. It causes dengue fever (DF), dengue hemorrhagic fever (DHF), or dengue shock syndrome (DSS), where DHF and DSS are life-threatening. Even though dengue is an age-old disease, it is still a mystery and continues to be a global threat. Numerous attempts have been carried out in the past few decades to eradicate the virus through vaccine and antiviral drugs, but still battle continues. In this review, the possible drug targets for discovery and development of potential antiviral drugs against structural proteins of dengue virus, the current development status of the antiviral drugs against dengue around the world, and challenges that need to be addressed to overcome the shortcomings in the process of drug discovery have been discussed. (C) 2021 Elsevier Masson SAS. All rights reserved.
机译:登革热病毒属于RNA病毒类和包膜单链阳性RNA病毒亚类。它会导致登革热(DF)、登革热出血热(DHF)或登革热休克综合征(DSS),其中DHF和DSS会威胁生命。尽管登革热是一种古老的疾病,但它仍然是一个谜,并继续是一个全球威胁。在过去几十年里,人们进行了无数次尝试,通过疫苗和抗病毒药物根除该病毒,但战斗仍在继续。本文讨论了发现和开发抗登革热病毒结构蛋白的潜在抗病毒药物的可能药物靶点,世界各地抗登革热抗病毒药物的发展现状,以及克服药物发现过程中的不足需要解决的挑战。(c)2021爱思唯尔马松SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号